ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
CDKN2A	1029	9404701	-	-	-	Tumor suppressor	20 (10 proliferative+ 10 secretory)	41	-	-	Shinshu University Hospital	I (n=28); II (n=5); III (n=7); IV (n=1)	1 (n=22); 2 (n=14); 3 (n=5)	[1] Increased expression of nuclear cdk4 associatedwith loss of p16INK4 expression could be involved in the carcinogenesis of asubset of endometrial carcinomas. [2] Topographically;the nuclear cdk4 positive tumor cells were negative for p16INK4 andthe nuclear p16INK4 positive tumor cells were found in areas without nuclear cdk4expression; suggesting an inverse correlation between the two agents.	Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma.	Cancer	80(12):2250-6	1997
CDKN2A	1029	10682682	-	-	-	-	-	35 endometrioid type + 18 endometrial hyperplasia + 12 atypical hyperplasia	-	-	-	I (n=23); II (n=5); III (n=6)	-	[1] The expression of p16 may be an early event in the neoplastic transformation of endometrial cancer. [2] p16 expression was significantly higher in EC than EH (P = 0.0119).	The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma.	British Journal of Cancer	82(3):675-82	2000
CDKN2A	1029	18949382	-	Down regulation/ Down expression	-	-	-	-	-	-	Shandong Tumor Hospital; China	-	-	[1] The microarray study shows that this gene is down-regulated by 0.138 fold in the tumor associated endometrium.	Gene alterations in tumor-associated endothelial cells from endometrial cancer.	International Journal of Molecular Medicine	22(5):619-32	2008